The North America Pain Management Devices Market is witnessing significant growth, propelled by technological advancements, rising prevalence of chronic pain, and a growing aging population. The market size was valued at USD 3,250 Million in 2025 and is expected to reach USD 7,190 Million by 2035, expanding at a CAGR of 7.8% from 2024 to 2035. Key companies driving innovation include Medtronic PLC, Boston Scientific Corporation, Abbott Laboratories, and B. Braun Melsungen AG.
The economic impact of tariffs on "North America Pain Management Devices Market".
Market Growth Drivers
Rising Prevalence of Chronic Diseases: The increasing prevalence of chronic conditions such as arthritis, cancer, and diabetes in North America is fueling demand for pain management devices. For example, according to the CDC, over 50 million adults in the US suffer from chronic pain, and this number is expected to rise. Companies like Medtronic have introduced devices such as spinal cord stimulators and implantable pumps to address chronic pain, significantly improving patients' quality of life and boosting market uptake.
Technological Advancements and Product Innovation: Leading companies are investing in research and development to launch advanced, minimally invasive pain management devices. Boston Scientific, for example, introduced the WaveWriter Alpha Spinal Cord Stimulator System featuring Bluetooth connectivity and personalized therapy settings. Such innovations enhance efficacy and patient comfort, resulting in increased adoption of pain management devices in clinical and homecare settings.
Market Trends
Increasing Adoption of Wearable Pain Management Solutions: The trend towards wearable and remote pain management systems is gaining momentum. Abbott Laboratories, for instance, introduced NeuroSphere myPath, a mobile app allowing patients to track their pain and share real-time data with physicians, supporting remote monitoring and personalized therapy adjustments. The expansion of telehealth initiatives and home-based care modalities further complements this trend.
Integration of AI and Smart Technology: Companies such as Stimwave Technologies are integrating artificial intelligence and smart technologies into pain management devices. These advancements enable real-time monitoring, predictive analytics, and automated therapy adjustments, resulting in improved patient outcomes and reduced healthcare costs. The combination of AI and connected devices is expected to shape the market landscape over the coming decade.
Market Opportunity
Expansion into Underserved Rural Regions: Major players, including B. Braun Melsungen AG, have the opportunity to expand their presence in rural and underserved regions of North America, where access to advanced pain management solutions remains limited. This could open new revenue streams and improve healthcare access for millions.
Growth of Non-Opioid Pain Management Solutions: With the ongoing opioid crisis, companies investing in non-opioid pain management devices, such as peripheral nerve stimulators, can capitalize on growing demand. Medtronic and SPR Therapeutics are rapidly expanding their portfolios to offer opioid-sparing alternatives.
North America Pain Management Devices Market Revenue (USD Million, 2020-2035)
The market revenue chart illustrates a steady upward trajectory for the North America Pain Management Devices Market from 2020 to 2035. In 2020, the market was valued at USD 2,010 Million, and by 2025, it reached USD 3,250 Million. Continuing this positive trend, the market is projected to grow robustly, attaining USD 7,190 Million by 2035. The chart reflects stable annual growth rates, propelled by increasing awareness, technological innovation, and a growing geriatric population that requires chronic pain care management. The influx of minimally invasive devices and the shift towards home-based care are key factors contributing to sustained revenue growth through the forecast period.
North America Pain Management Devices Market Share by Region (%), 2025
The 2025 market share pie chart reveals that the United States leads the North America Pain Management Devices Market, accounting for 71% of total market revenue. Canada follows with 20%, while Mexico holds a 6% share. The remaining 3% is split between other North American regions, including Puerto Rico and Bermuda. The dominance of the US is attributed to its advanced healthcare infrastructure, higher adoption rates for innovative devices, and a large patient base. Canada’s share is supported by increased investments in public health and technology adoption, whereas Mexico and other regions are emerging markets with growth potential as healthcare access improves.
Recent Developments
In May 2024, Medtronic received FDA approval for its latest Intellis™ rechargeable spinal cord stimulator, designed for superior battery life and MRI compatibility. The device supports remote programming, enabling physicians to adjust therapy settings virtually, significantly enhancing patient convenience and therapy outcomes.
In April 2024, Boston Scientific launched the FAST Therapy™ feature for its SCS systems, offering real-time pain relief customization and faster patient response rates. This innovation combines high-frequency stimulation and personalized algorithms, reinforcing the company’s leadership in neuromodulation technology.
In March 2024, Abbott secured Health Canada approval for its Proclaim XR SCS System, targeting patients with chronic lower back pain. The system leverages advanced low-dose stimulation technology, providing effective pain relief while preserving battery life, and is now being rolled out across major Canadian healthcare centers.
Press Releases